Effects of Meloxicam and Indomethacin on Cyclooxygenase Pathways in Healthy Volunteers

Journal of Investigative Medicine

Volumn 45, Issue 2, 1997, Pages 44-49

  Stichtenoth, Dirk O ^a   Wagner, Bettina ^a   Frölich, Jürgen C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cyclooxygenase isoenzymes; Indomethacin; Meloxicam; Platelet aggregation; Prostanoid formation

Indexed keywords

7 HYDROXY 5,11 DIOXOTETRANORPROSTANE 1,16 DIOIC ACID; 7-HYDROXY-5,11-DIOXOTETRANORPROSTANE-1,16-DIOIC ACID; INDOMETACIN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; THROMBOXANE B2;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; URINE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; INDOMETHACIN; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; THERAPEUTIC EQUIVALENCY; THIAZINES; THIAZOLES; THROMBOXANE B2;

EID: 0031063550     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing Proc Natl Acad Sci USA 1991;88:2692-6.
2. Kujubu DA, Fletcher BS, Varnum CR, Lim W, Herschman H. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
3. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-9.
4. Frölich JC. Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition. Ann Rheum Dis 1995;54:942-3.
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology 1971;231:232-5.
6. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature: New Biology 1971;231:235-7.
7. Vane JR. Towards a better aspirin. Nature 1994;367:215-6.
8. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
9. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane JR, Botting JH, Botting RM, eds. Improved nonsteroid anti-inflammatory drugs: COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers, William Harvey Press, 1996:103-19.
10. Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. In vitro and in vivo findings. Biochem Pharmacol 1996;51(pt. 1):21-8.
11. Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic metabolism. In vitro and in vivo findings. Biochem Pharmacol 1996;51(pt. 2):29-38.
12. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-12.
13. Frölich JC, Wilson TW, Sweetman BJ, Smigel M, Nies AS, Carr K, Watson JT, Oates JA. Urinary prostaglandins. Identification and origin. J Clin Invest 1975;55:763-70.
14. Seyberth HW, Sweetman BJ, Frölich JC, Oates JA. Quantification of the major urinary metabolite of the E-prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976;11:381-97.
15. 2 in healthy men. Prostaglandins 1979;16:623-9.
16. Ferretti A, Flanagan VP, Reeves VB. Stable isotope dilution assay for prostaglandin E metabolite: 24-hour urinary output in healthy male subjects. Anal Biochem 1987;167:174-80.
17. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996;35(1 Suppl):39-43.
18. Goei Thé H, Lund B, Bluhmki E. A double-blind, randomised trial comparing meloxicam with diclofenac in osteoarthritis (OA). Rheumatology in Europe 1995:24(3 Suppl):E51.
19. Türck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1996;15:23-30.
20. Reynolds JEF, ed. Martindale, the extra pharmacopoeia, 30th ed. London: Pharmaceutical Press, 1993:19-21.
21. Böger RH, Bode-Böger SM, Gutzki F-M, Tsikas D, Weskott H-P, Frölich JC. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low-dose aspirin in man. Clin Sci (Colch) 1993;84:517-24.
22. Fauler J, Tsikas D, Mayatepek E, Keppler D, Frölich JC. Impaired degradation of prostaglandins and thromboxane in Zellweger syndrome. Pediatr Res 1994;36:449-55.
23. Lichtenstein DR, Syngal S, Wolfe M. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Arthritis Rheum 1995;38:5-18.
24. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35(1 Suppl):68-77.
25. Frölich JC, Stichtenoth DO. NSAID: can renal side effects be avoided? In: Vane JR, Botting JH, Botting RM. eds. Improved non-steroid anti-inflammatory drugs: COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers 1996:203-28.
26. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med 1990;112:568-76.
27. Oliver JA, Sciacca RR, Pinto J, Cannon JA. Participation of prostaglandins in the control of renal blood flow during acute reduction of cardiac output in the dog. J Clin Invest 1981;67:229-37.
28. Zipser RD. Role of renal prostaglandins and the effects of non-steroidal anti-inflammatory drugs in patients with liver disease. Am J Med 1986;81(26 Suppl):95-103.
29. Bevis PJR, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996;35(1 Suppl):56-60.
30. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-60.
31. Reginster JY, Distel M, Bluhmki E. A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(1 Suppl):17-21.
32. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30, and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994;98(Suppl):A115.
33. Wojtulewski JA, Schattenkirchner M, Barceló P, Le Loet X, Bevis PJR, Bluhmki E, Distel M. A six-month, double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Brit J Rheumatol 1996;35(1 Suppl):22-8.